PDCD1 and non-small cell lung carcinoma: Given that both SMI and PD-1/PD-L1 inhibitors primarily induce immunomodulatory effects and impact similar immune cells, we investigated whether the combination of SMI and ICIs exerts synergistic antitumor effects with minimal irAEs in NSCLC.